Verve Therapeutics Reports New Preclinical Data Demonstrating Potent and Durable Editing of ANGPTL3 Gene with VERVE-201 in Wild-type and LDLR-deficient Non-Human Primates

VERVE-201 Preclinical Data Supports Advancement of Drug Candidate Toward Clinical Development for Homozygous Familial Hypercholesterolemia, with Initiation of Clinical Trial Anticipated in 2024 Data... | March 3, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Jen Robinson ,Andrew Bellinger ,Exchange Commission ,Editing Medicine Targeting ,Clinical Development For Homozygous Familial Hypercholesterolemia ,Ernestn Morial Convention Center ,Nasdaq ,Verve Therapeutics Inc ,Data Supports Advancement ,Drug Candidate Toward Clinical Development ,Homozygous Familial Hypercholesterolemia ,Clinical Trial Anticipated ,Presented During ,Oral Presentation ,Annual Scientific Sessions ,Preclinical Data Supporting Potential Efficacy ,Primary Human Cells ,Highlighted Original Research ,Ischemic Heart Disease ,Convention Center ,Private Securities Litigation Reform Act ,Verve Therapeutics ,Nc Stock Exchange ,News ,Information ,Press Release ,Reclinical ,Data ,Supports ,Advancement ,F ,Drug ,Candidate ,Howard ,Linical ,Development ,Or ,Omozygous ,Familial ,Ith ,Initiation ,Trial ,Nticipated ,N ,024 Verv Us92539p1012 ,